I-Mab to rebrand as NovaBridge and target Hong Kong dual listing
US-China biotech I-Mab (Nasdaq: IMAB) is planning a strategic overhaul that includes a new name, NovaBridge Biosciences, and a dual listing on the Hong Kong Stock Exchange alongside its existing Nasdaq position. Shareholders will vote on the rebrand at an extraordinary meeting on October 24.
The company said the changes mark its evolution into a global biotech platform, emphasizing business development and translational clinical development. Executive chairman Fu Wei described the shift as positioning I-Mab to accelerate access to innovation by partnering with global players and attracting new pools of capital across Asia.
As part of the transition, I-Mab is launching Visara, a subsidiary focused on ophthalmic therapies. Visara will acquire VIS-101, a bifunctional biologic designed to target VEGF-A and Ang-2. The therapy is in Phase II testing and is expected to be Phase III-ready in 2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze